Table 1.
Data are presented as mean ± SD, independent, two-tailed, t-tests were used to test statistical significance. BMI, body mass index, low (LDL and high (HDL) density lipoproteins, hematocrit (Hct), Hemoglobin (Hb), 17 β-estradiol (E2). *n=6 for transmen for E2 values. Based on clinical practice guidelines, E2 levels are no longer measured once an the E2 level is consistently below 50 pg/ml, menses stop or the individual has had total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH/BSO). We removed one E2 outlier from the TGM group (668.1 pmol/L) as this was an inconsistent finding within this subject. We elected to keep this subject in the study because his testosterone was within range and FMD was also low. Significance was accepted at P < 0.05 and indicated in boldface in the table.
| Transgender Men | Cisgender Women | P | |
|---|---|---|---|
| n | 10 | 20 | |
| Age, y | 27 ± 4 | 28 ± 5 | 0.389 |
| Race (Asian/Black/White/Hispanic) | (2/1/6/1) | (2/3/12/3) | NA |
| Weight, kg | 66.8 ± 10.1 | 71.1 ± 14.0 | 0.386 |
| Height, cm | 165.4 ± 7.6 | 166.9 ± 8.1 | 0.642 |
| BMI, kg/m2 | 24.4 ± 14.9 | 26.0 ± 5.1 | 0.392 |
| HbA1C, % | 5.0 ± 0.2 | 4.7 ± 0.4 | 0.048 |
| Total Cholesterol, mmol/L | 40 ± 15 | 46 ± 9 | 0.785 |
| LDL, mmol/L | 26 ± 6 | 25 ± 6 | 0.820 |
| HDL, mmol/L | 12 ± 5 | 16 ± 4 | 0.146 |
| Triglycerides, mmol/L | 0.9 ± 0.5 | 0.9 ± 0.4 | 0.501 |
| Hct, % | 43.2±1.9 | 39.9±2.9 | 0.002 |
| Hb, mmol/L | 8.8±0.6 | 8.9±1.2 | 0.683 |
| E2, pmol/L* | 167.7±62.4 (n=6) | 222.4±126.6 (n=20) | 0.325 |
| Total Testosterone, nmol/L | 1763 ± 270 Range, 866–3813 | 5 ± 2 Range, 2 –8 | 5.678e−22 |
| Free Testosterone, nmol/L | 0.30 ± 0.13 range: 0.15–0.78 | 0.05 ± 0.02 range: 0.02–0.08 | 6.106e−11 |